Bausch + Lomb Corporation is an eye health company that operates globally, focusing on three main segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment generates approximately 40% of revenue through contact lenses and related products, while the Ophthalmic Pharmaceuticals segment contributes around 30% with both proprietary and generic eye medications. The Surgical segment accounts for about 30% of revenue, providing surgical tools and technologies for cataract and retinal treatments. Factors supporting the company's endurance include its long history and established brand in eye health, while challenges may arise from competition and pricing pressures in the pharmaceutical and consumer health markets.
—
Bausch + Lomb Corporation is an eye health company that operates globally, focusing on three main segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment generates approximately 40% of revenue through contact lenses and related products, while the Ophthalmic Pharmaceuticals segment contributes around 30% with both proprietary and generic eye medications. The Surgical segment accounts for about 30% of revenue, providing surgical tools and technologies for cataract and retinal treatments. Factors supporting the company's endurance include its long history and established brand in eye health, while challenges may arise from competition and pricing pressures in the pharmaceutical and consumer health markets.
—
Daily adjusted close
Bausch + Lomb Corporation is an eye health company that operates globally, focusing on three main segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment generates approximately 40% of revenue through contact lenses and related products, while the Ophthalmic Pharmaceuticals segment contributes around 30% with both proprietary and generic eye medications. The Surgical segment accounts for about 30% of revenue, providing surgical tools and technologies for cataract and retinal treatments. Factors supporting the company's endurance include its long history and established brand in eye health, while challenges may arise from competition and pricing pressures in the pharmaceutical and consumer health markets.